New study checks bleeding risk when CLL drug meets blood thinners
NCT ID NCT05517265
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this combination. The study did not test a new treatment but aimed to gather real-world safety data to help doctors manage bleeding risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prof. Dr. Fenchel & Dr. Winkler MVZ Träger GbR
Saalfeld, Thuringia, 07318, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Zinc-Based compound fight cancer?
- Lab-Grown lymph node model reveals how CLL cells resist treatment
- New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
- New combo therapy aims to wipe out hidden leukemia cells
- New CAR-T therapy targets BAFF-R to fight resistant lymphoma
- Massive new registry to track thousands of blood cancer patients for years